108 related articles for article (PubMed ID: 80268)
1. Pharmacokinetic considerations in evaluating the effects of tetrahydrouridine on 5-azacytidine chemotherapy in L1210 leukemic mice.
Kelly CJ; Gaudio L; Yesair DW; Schoenemann PT; Wodinsky I
Cancer Treat Rep; 1978 Jul; 62(7):1025-32. PubMed ID: 80268
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology of combination chemotherapy of cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) or tetrahydrouridine (THU) against murine leukemia L1210/0 in tumor-bearing mice.
Avramis VI; Powell W
Cancer Invest; 1987; 5(4):293-9. PubMed ID: 3664332
[TBL] [Abstract][Full Text] [Related]
3. Enhancement by tetrahydrouridine (NSC-112907) of the oral activity of 5-azacytidine (NSC-102816) in L1210 leukemic mice.
Neil GL; Moxley TE; Kuentzel SL; Manak RC; Hanka LJ
Cancer Chemother Rep; 1975; 59(3):459-65. PubMed ID: 54211
[TBL] [Abstract][Full Text] [Related]
4. Combination chemotherapy of L1210 leukemia with 1-beta-D-arabinofuranosylcytosine and 5-azacytidine.
Neil GL; Berger AE; Bhuyan BK; DeSante DC
Cancer Res; 1976 Mar; 36(3):1114-20. PubMed ID: 56229
[TBL] [Abstract][Full Text] [Related]
5. Combinations of tetrahydrouridine and cytosine arabinoside in mouse tumors.
Kreis W; Hession C; Soricelli A; Scully K
Cancer Treat Rep; 1977 Oct; 61(7):1355-64. PubMed ID: 589601
[TBL] [Abstract][Full Text] [Related]
6. Tetrahydrouridine: Physiologic disposition and effect upon deamination of cytosine arabinoside in man.
Kreis W; Woodcock TM; Gordon CS; Krakoff IH
Cancer Treat Rep; 1977 Oct; 61(7):1347-53. PubMed ID: 589600
[TBL] [Abstract][Full Text] [Related]
7. Kinetics of both leukemic and normal cell population reduction following 5-azacytidine.
Presant CA; Vietti T; Valeriote F
Cancer Res; 1975 Aug; 35(8):1926-30. PubMed ID: 50128
[TBL] [Abstract][Full Text] [Related]
8. Effect of 3-deazauridine on the metabolism, toxicity, and antitumor activity of azacitidine in mice bearing L1210 leukemia sensitive and resistant to cytarabine.
Li ZR; Campbell J; Rustum YM
Cancer Treat Rep; 1983 Jun; 67(6):547-54. PubMed ID: 6190558
[TBL] [Abstract][Full Text] [Related]
9. Use of uridine rescue to enhance the antitumor selectivity of 5-fluorouracil.
Klubes P; Cerna I
Cancer Res; 1983 Jul; 43(7):3182-6. PubMed ID: 6850628
[TBL] [Abstract][Full Text] [Related]
10. Effect of tetrahydrouridine on the clinical pharmacology of 1-beta-D-arabinofuranosylcytosine when both drugs are coinfused over three hours.
Kreis W; Chan K; Budman DR; Schulman P; Allen S; Weiselberg L; Lichtman S; Henderson V; Freeman J; Deere M
Cancer Res; 1988 Mar; 48(5):1337-42. PubMed ID: 3342412
[TBL] [Abstract][Full Text] [Related]
11. Influence of tetrahydrouridine on the pharmacokinetics of intrathecally administered 1-beta-D-arabinofuranosylcytosine.
Riccardi R; Chabner B; Glaubiger DL; Wood J; Poplack DG
Cancer Res; 1982 May; 42(5):1736-9. PubMed ID: 6896013
[TBL] [Abstract][Full Text] [Related]
12. Contrasting cytotoxicity kinetics of 5-azacytidine and dihydro-5-azacytidine hydrochloride in L1210 leukemia in mice.
Presant CA; Coulter D; Valeriote F; Vietti TJ
J Natl Cancer Inst; 1981 Jun; 66(6):1151-4. PubMed ID: 6165854
[TBL] [Abstract][Full Text] [Related]
13. Phase I evaluation of tetrahydrouridine combined with cytosine arabinoside.
Wong PP; Currie VE; Mackey RW; Krakoff IH; Tan CT; Burchenal JH; Young CW
Cancer Treat Rep; 1979 Aug; 63(8):1245-9. PubMed ID: 383291
[TBL] [Abstract][Full Text] [Related]
14. Distribution of tetrahydrouridine in experimental animals.
el-Dareer SM; White V; Chen FP; Mellett LB; Hill DL
Cancer Treat Rep; 1976 Nov; 60(11):1627-31. PubMed ID: 828522
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy of L1210 leukemia with 5-azacytidine in combination with vincristine, adriamycin, or beta-cytosine arabinoside.
Presant CA; Vietti TJ; Valeriote F; Coulter DM
J Natl Cancer Inst; 1981 Dec; 67(6):1283-8. PubMed ID: 6171666
[TBL] [Abstract][Full Text] [Related]
16. Comparative studies of the cytostatic action and metabolism of 5-azacytidine and 5,6-dihydro-5-azacytidine.
Voytek P; Beisler JA; Abbasi MM; Wolpert-DeFilippes MK
Cancer Res; 1977 Jul; 37(7 Pt 1):1956-61. PubMed ID: 67884
[TBL] [Abstract][Full Text] [Related]
17. Use of 5-fluorodeoxycytidine and tetrahydrouridine to exploit high levels of deoxycytidylate deaminase in tumors to achieve DNA- and target-directed therapies.
Mekras JA; Boothman DA; Perez LM; Greer S
Cancer Res; 1984 Jun; 44(6):2551-60. PubMed ID: 6539164
[TBL] [Abstract][Full Text] [Related]
18. Enhancement by tetrahydrouridine of 1-beta-D-arabinofuranosylcytosine (cytarabine) oral activity in L1210 leukemic mice.
Neil GL; Moxley TE; Manak RC
Cancer Res; 1970 Aug; 30(8):2166-72. PubMed ID: 4990003
[No Abstract] [Full Text] [Related]
19. Effect of tetrahydrouridine on the action of 1-beta-D-arabinofuranosylcytosine in synchronized cultures of normal rat kidney cells.
Wan CW; Mak TW
Cancer Res; 1979 Oct; 39(10):3981-5. PubMed ID: 476637
[TBL] [Abstract][Full Text] [Related]
20. The disposition and pharmacokinetics in humans of 5-azacytidine administered intravenously as a bolus or by continuous infusion.
Israili ZH; Vogler WR; Mingioli ES; Pirkle JL; Smithwick RW; Goldstein JH
Cancer Res; 1976 Apr; 36(4):1453-61. PubMed ID: 57000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]